BioSpace News Archive

Aucta Pharmaceuticals, Inc. (Aucta) has partnered with Oakrum Pharma, out of St. Louis, Missouri, to announce the U.S. launch of a generic version of JADENU® Sprinkle (Deferasirox Granules) in 90mg, 180mg, and 360mg strengths.

KT Corporation and NeuroSigma, Inc. jointly announced signing of a memorandum of understanding, forming a strategic partnership to develop and commercialize, inside and outside of Korea, electronic therapies treating neurological and neuropsychological disorders, including ADHD, depression, and epilepsy.

Cognito Therapeutics, announced today its plans to add a second digital therapeutic to the company’s pipeline, initiating a new study evaluating digital therapeutic for individuals who have the genetic rare disease, Down syndrome associated Alzheimer’s Disease (DS-AD).

Goldfinch Bio, a clinical stage biotechnology company focused on discovering and developing precision medicines for the treatment of kidney diseases, announced that Anthony Johnson, M.D., Chief Executive Officer of Goldfinch Bio, will present a corporate overview at the Raymond James Human Health Innovations Conference on Monday, June 21, 2021 at 9:20 a.m. ET.

Expansion Therapeutics, Inc., today announced the appointment of Mark Ledeboer, Ph.D. to Senior Vice President of Drug Discovery.

Amylyx Pharmaceuticals, Inc., a pharmaceutical company focused on developing new treatments for amyotrophic lateral sclerosis (ALS), Alzheimer’s Disease and other neurodegenerative diseases, today announced it has submitted a New Drug Submission (NDS) to Health Canada for AMX0035 (sodium phenylbutyrate (PB)-taurursodiol (TURSO)) for the treatment of ALS

Twist Bioscience Corporation today announced that CEO Emily Leproust will participate in a fireside chat at the BIO Digital conference.

Agilent Technologies Inc. (NYSE: A) today announced that Stéphane Bayen has received an Agilent Thought Leader Award.

Terns Pharmaceuticals, Inc. reported positive top-line results from the Phase 2a LIFT clinical trial of TERN-101, a liver-distributed farnesoid X receptor agonist for the treatment of patients with NASH.

Nevro Corp. today announced it will host an analyst & investor briefing from the American Diabetes Association 81st Scientific Sessions on Friday, June 25, 2021, beginning at 3:30 pm PT / 6:30 pm ET.